LBBW keeps EUR 29.00 target for Gerresheimer stock

Published on 10/15/2026 at 15:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted EBITDA hit EUR 102 million on September 30, 2026. Gerresheimer stock costs EUR 29.41 on October 15, 2026, 0.24 percent below the Xetra close.

Analyst target and trading range

LBBW raised its Gerresheimer target to EUR 29.00 on October 6, 2026.
Adjusted EBITDA reached EUR 102 million in the second quarter of 2026.
Gerresheimer stock costs EUR 29.41 at Lang & Schwarz on October 15, 2026 at 2:41 p.m. CEST, 0.24 percent below the Xetra close of October 14, 2026.
The next half-year financial report is scheduled for November 2026.

Aquarellmalerei einer deutschen Rheinstadt-Skyline bei Abenddämmerung — Gerresheimer AG, ISIN DE000A0LD6E6, sitzt in einer deutschen Rheinstadt mit malerischer Aquarell-Skyline dargestellt, Illustration mit AI erstellt.

LBBW raised its price target for Gerresheimer from EUR 28.00 to EUR 29.00 and kept its Hold rating on October 6, 2026, according to Goldesel. Gerresheimer stock stood 1.41 percent above that target. At Lang & Schwarz, the stock was trading at EUR 29.41 on October 15, 2026 at 2:41 p.m. CEST, minus 0.24 percent versus the Xetra close of October 14, 2026 at EUR 29.48.

Second-quarter earnings improved sequentially

Gerresheimer reported adjusted earnings before interest, taxes, depreciation and amortization of EUR 102 million for the second quarter of 2026, up from EUR 67 million in the first quarter. Revenue reached EUR 578 million, an increase of EUR 55 million from the first quarter, while remaining below the EUR 614 million recorded in the second quarter of 2025, according to FT.com. The adjusted earnings margin reached 17.6 percent in the quarter.

Stock remains below yearly high

The current EUR 29.41 price is 8.09 percent below the 52-week high of EUR 32.00 and 98.31 percent above the low of EUR 14.83, both as of October 15, 2026. Trading volume stood at 76,867 shares against an average of 150,440 shares. The bid was EUR 29.30 and the ask EUR 29.52.

Valuation and reporting calendar

Gerresheimer's market capitalization was EUR 1.0 billion as of October 15, 2026. The investor-relations calendar lists the next half-year financial report for November 2026 and a third-quarter statement for November 2026, according to Gerresheimer. The company kept its 2026 outlook for revenue in the lower half of the EUR 2.3 billion to EUR 2.4 billion range and an adjusted earnings margin of 17 percent to 18 percent, as reported by Investing.com on September 30, 2026.

Comparison with peers

Gerresheimer (Xetra, EUR): minus 0.24 percent, market capitalization EUR 1.0 billion
SCHOTT Pharma (Frankfurt, EUR): minus 0.41 percent, P/E 26.81, market capitalization EUR 3.7 billion
Sartorius (Xetra, EUR): plus 0.97 percent, P/E 91.66, market capitalization EUR 18.0 billion

Price and trading position

Gerresheimer's stock was trading at EUR 29.41 at Lang & Schwarz on October 15, 2026 at 2:41 p.m. CEST, 0.24 percent below the Xetra close of October 14, 2026 at EUR 29.48. The price remains below the 52-week high while the second-quarter operating recovery provides the latest reported earnings comparison.

The further course of trading is shown by the continuously updated real-time quote of Gerresheimer stock.